Bud-wiser: DOD Backs A-Alpha Bio for Biothreat Preparation
A-Alpha Bio will use its yeast display platform to accelerate drug discovery against an expanded list of possible biological threats.
A-Alpha Bio will use its yeast display platform to accelerate drug discovery against an expanded list of possible biological threats.
Genes show modern Maya are related to the children’s ancient community
Scientists found that FUS protein aggregates in FTLD and ALS act like seeds causing more clusters to form and spread throughout the brain.
As temperatures and evidence of climate impacts mount, so too do pressures to enhance climate policy ambition and implementation. In a previous piece, I have…
FDA advisers say new shots can target more recent SARS-CoV-2 variants
London, United Kingdom–(Newsfile Corp. – June 15, 2024) – Deepwrk is thrilled to announce the launch of a digital platform, designed specifically for the neurodivergent…
Aaron Gani, CEO and founder of RealizedCare, discusses the evolution of digital therapeutics, the FDA’s place in advancing them, keeping up with evolving technology, and…
Sibylla’s PPI-FIT technology is used to discover and develop FIDs, small molecules that induce the degradation of target proteins.
EPAM Systems, an NYSE-listed leading digital transformation services and product engineering company has announced the acquisition of Odysseus Data Services, Inc a health data analytics…
More than any other cell therapy, there’s a critical interplay between processes and analytics with macrophages.
Researchers in Limerick developed a framework to help biopharmaceutical manufacturers turn data into actionable, trustworthy information.